You are here: Industry Insights > bowel cancer

News List

Regular dose of aspirin can lower risk of inherited bowel cancer: Study expresspharma
June 15, 2020
The research, carried out by Universities of Newcastle and Leeds, and funded by Cancer Research UK, NIHR, Bayer Pharma AG and the Barbour Foundation ...
Te Herenga Waka—Victoria University, NZ professor receives funding boost for vaccine research expresspharma
June 03, 2020
Te Herenga Waka—Victoria University of Wellington Associate Professor Bridget Stocker has received a significant funding boost for vaccine research that has potential to help with diseases ranging from bowel cancer to COVID-19.
Cancer Research UK to fund three international research projects pharmaceutical-technology
January 25, 2019
Cancer Research UK is set to fund three new international research projects focused on better understanding the microbiome in human bodies.....
Emergency hospital visits more likely for deprived bowel cancer patients pharmatimes
August 16, 2018
Emergency hospital visits are more common among patients with bowel cancer living in the most deprived areas of the country than for those living in affluent regions, research funded by Cancer Research UK has found.
Bowel cancer screening to start 10 years earlier pharmatimes
August 14, 2018
Bowel cancer screening in England and Wales is to start a decade earlier in a drive to pick up more cases of the disease at an earlier stage, the government has confirmed.
Hospitals failing to test for Lynch syndrome pharmatimes
July 20, 2018
Hospitals across the UK are failing to test all bowel cancer patients at the time of their diagnosis for a genetic condition called Lynch syndrome, which significantly increases the risk of developing cancer over a lifetime.
Research backs halving chemo after bowel cancer surgery pharmatimes
July 19, 2018
Some patients receiving chemotherapy after surgery for bowel cancer might only need three months of treatment rather than the six months currently given, according to new research published in the Lancet Oncology.